Trinity Biotech plc (TRIB)
NASDAQ: TRIB · Real-Time Price · USD
0.6520
-0.0260 (-3.83%)
At close: Jun 27, 2025, 4:00 PM
0.6521
+0.0001 (0.02%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Trinity Biotech Revenue
In the year 2024, Trinity Biotech had annual revenue of $61.56M with 8.31% growth. Trinity Biotech had revenue of $15.86M in the quarter ending December 31, 2024.
Revenue (ttm)
$61.56M
Revenue Growth
+8.31%
P/S Ratio
0.17
Revenue / Employee
$153,504
Employees
401
Market Cap
12.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61.56M | 4.72M | 8.31% |
| Dec 31, 2023 | 56.83M | -5.69M | -9.10% |
| Dec 31, 2022 | 62.52M | -18.63M | -22.96% |
| Dec 31, 2021 | 81.15M | -20.83M | -20.43% |
| Dec 31, 2020 | 101.98M | 11.55M | 12.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
TRIB News
- 4 days ago - Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation - GlobeNewsWire
- 6 weeks ago - Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update - GlobeNewsWire
- 3 months ago - Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 3 months ago - Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process - GlobeNewsWire
- 4 months ago - Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology - GlobeNewsWire
- 5 months ago - Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial - GlobeNewsWire
- 5 months ago - Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology - GlobeNewsWire
- 6 months ago - Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan - GlobeNewsWire